Ravicti
Horizon receives European go-ahead for Ravicti
December 2, 2015Research and Development, Sales and Marketing Horizon Pharma, Ravicti, horizon, orphan drug, rare disease, urea cycle disorders
The European Commission has approved Ravicti for rare urea cycle disorders. Ravicti, (glycerol phenylbutyrate), is an oral liquid developed by Horizon …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
